Please ensure Javascript is enabled for purposes of website accessibility


Jan 18, 2022

Johns Hopkins, Orgenesis to create Maryland Center for Cell Therapy Manufacturing

Johns Hopkins Medicine and biotech company Orgenesis are collaborating on the Maryland Center for Cell Therapy Manufacturing.

Apr 28, 2021

Two Md. companies chosen for inaugural health care incubator cohort

Baltimore-based health care innovation incubator 1501 Health announced its inaugural cohort of companies at a virtual ribbon-cutting ceremony on Wednesday. Each of the five start-ups, two of which are based in Maryland and the remainder of which are from California, seek to address gaps in health care, from connecting patients with holistic health services to lessening stigma around getting [...]

Mar 26, 2020

Md. biotech firms working together on coronavirus responses

Traditionally competitive life sciences companies in Maryland have begun to collaborate as they develop tests, therapies and vaccines for COVID-19.

Oct 10, 2019

Why KaloCyte picked Baltimore and the BioPark

The University of Maryland BioPark and proximity to key stakeholders were two of the top reasons KaloCyte decided to move to Baltimore, its CEO said. The company that is developing an artificial red blood cell moved to Baltimore from St. Louis last month. “While we benefited greatly from our roots at St. Louis … as […]

Oct 3, 2019

Viela Bio shares close up big on firm’s first day of trading

Gaithersburg-based biotech firm Viela Bio made a splash in its stock market debut Thursday, closing 23% above its initial share price and allaying fears of a depressed IPO market. Viela sold 7.9 million common shares in its initial public offering as it sought to raise $150 million. The firm’s share price jumped as high as […]

Sep 11, 2019

Baltimore cancer test startup wins pitch competition for veterans

A Baltimore biotech startup won a pitch competition in Utah last month, the latest sign that companies that make it easier to diagnose treatable cancers could be a significant part of Maryland’s biotech economy. Capsulomics and its early detection test for esophageal cancer join a growing field that includes Thrive Early Detection Corp., another Johns […]

Sep 3, 2019

Gaithersburg-based Viela Bio files for $150M IPO

Viela Bio, the MedImmune spinout that has attracted more than $300 million in venture capital, filed for a $150 million initial public offering last week.

Jul 11, 2019

California biotech company makes UM BioPark its first East Coast location

California biotech firm Illumina will make the University of Maryland BioPark its first East Coast location, another major tenant for the research park now overflowing with tenants. Illumina, a developer, manufacturer and marketer of biotech tools especially for use in genomic sequencing, is expected to generate more visitors for the BioPark as other companies send […]

Jun 5, 2019

AltImmune gets drug patent; notified of 2nd patent coming

A Gaithersburg biotechnology company has received additional patent protection for two of its programs. Altimmune Inc. announced Wednesday it had been granted a patent for a drug, HepTcell, for people chronically infected with the hepatitis B virus. The patent expires in 2035. The company said in a news release that it is working on putting […]

May 30, 2019

Hopkins company raises $110 million to develop cancer test

A startup developing technology originating at Johns Hopkins that offers early detection of cancers launched Thursday with $110 million in Series A funding, a record Series A round for a Johns Hopkins company. Thrive Earlier Detection Corp. will develop CancerSeek, a liquid biopsy that tests for eight different forms of common cancers. “This is a […]

Apr 17, 2019

Paragon acquisition gives a jolt to Md. biotech industry

Ten years ago, Paragon Bioservices moved into the University of Maryland BioPark with just 30 employees and a change of direction to focus on manufacturing gene therapies. Monday the firm announced that it had agreed to be acquired by Catalent Biologics in a more than $1.2 billion deal expected to be completed this quarter. It […]

Apr 15, 2019

Paragon acquired by NJ-based Catalent for $1.2 billion

Baltimore biotech firm Paragon Bioservices has been acquired by the New Jersey-based drug manufacturer Catalent, Inc. for $1.2 billion, Paragon announced Monday. Paragon, which specializes in biologics contract development and manufacturing, especially in gene therapy using viral vector manufacturing, employs about 380 people in Maryland and just opened a new manufacturing facility in Anne Arundel[...]

Networking Calendar

Submit an entry for the business calendar